Nimodipine in the treatment of old age dementias
- PMID: 2236581
- DOI: 10.1016/0278-5846(90)90005-2
Nimodipine in the treatment of old age dementias
Abstract
1. In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias. 2. Treatment with 90 mg of nimodipine administered orally in divided doses for 12 weeks was significantly superior to an inactive placebo on all outcome measures including the Wechsler Memory Scale, the Mini Mental State Examination, the Global Deterioration Scale, the Sandoz Clinical Assessment Geriatric Scale, the Plutchik Geriatric Rating Scale, the Severity of Illness and Global Improvement Scales of Clinical Global Impression, and the Hamilton Psychiatric Rating Scale for Depression. 3. Adverse effects with nimodipine were few and mild. The drug was equally well tolerated and equally effective in the two major dementias of old age, i.e., primary degenerative and multi-infarct. The number of abnormal laboratory test readings remained essentially unchanged from pre-treatment to post-treatment.
Similar articles
-
Glycosaminoglycan polysulfate in the treatment of old age dementias.Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(3):323-42. doi: 10.1016/0278-5846(91)90064-8. Prog Neuropsychopharmacol Biol Psychiatry. 1991. PMID: 1862217 Clinical Trial.
-
Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group.Clin Ther. 1993 Mar-Apr;15(2):394-406. Clin Ther. 1993. PMID: 8519047 Clinical Trial.
-
The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia.J Neurol Sci. 2000 Apr 15;175(2):116-23. doi: 10.1016/s0022-510x(00)00301-4. J Neurol Sci. 2000. PMID: 10831772 Clinical Trial.
-
Clinical aspects of nimodipine.Clin Neuropharmacol. 1993;16 Suppl 1:S39-45. doi: 10.1097/00002826-199316001-00006. Clin Neuropharmacol. 1993. PMID: 8519001 Review.
-
Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes.Int Psychogeriatr. 1992;4 Suppl 1:89-99. Int Psychogeriatr. 1992. PMID: 1504290 Review.
Cited by
-
Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav 1.2).Eur J Neurosci. 2015 Oct;42(8):2499-507. doi: 10.1111/ejn.12952. Epub 2015 Jun 23. Eur J Neurosci. 2015. PMID: 25989111 Free PMC article.
-
Advances in the pharmacotherapy of Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 1994;244(5):261-71. doi: 10.1007/BF02190379. Eur Arch Psychiatry Clin Neurosci. 1994. PMID: 7893772 Review.
-
Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.Drugs Aging. 1999 Mar;14(3):197-230. doi: 10.2165/00002512-199914030-00004. Drugs Aging. 1999. PMID: 10220105 Review.
-
Nimodipine in otolaryngology: from past evidence to clinical perspectives.Acta Otorhinolaryngol Ital. 2015 Jun;35(3):135-45. Acta Otorhinolaryngol Ital. 2015. PMID: 26246657 Free PMC article. Review.
-
Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.Drugs Aging. 1992 Jul-Aug;2(4):262-86. doi: 10.2165/00002512-199202040-00002. Drugs Aging. 1992. PMID: 1504442 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical